ONE NUCLEUS STRENGTHENS BOARD WITH APPOINTMENT OF NEW DIRECTOR

Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024

Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
Who we are
We are currently looking for a Health and Safety Consultant to join our small team at Health & Safety Works.
Our team is based in East Anglia, and all consultants work from home. You may however need to travel further afield.
An exciting opportunity has arisen for a Postdoctoral Researcher to join the Whitewoods Group at the John Innes Centre, working on cutting-edge science in the field of Cell & Development Biology.
About the Whitewoods Group
LONDON, UK and VALENCIA, Spain – June 2, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Quibim and is pleased to announce the placement of Itta MacNevin as Chief Business Officer (CBO).
We have an exciting opportunity to take on a key leadership role as Facilities Manager at Mills & Reeve's Cambridge office.
The role
Xampla is seeking a Business Development and Sales Lead (Licensees, Mills and Coaters) to drive commercial growth and take full ownership of how we scale our coatings business globally.
This is about more than sales delivery: it’s about shaping our commercial strategy, building deep partnerships across the paper coatings value chain, and positioning Xampla as a trusted partner for sustainable materials innovation.
ELRIG’s Drug Discovery 2026 is back at London’s Excel, and as Europe’s leading drug discovery and life sciences conference, it will have scientific tracks covering topics including Next Generation biophysics, microbes to medicines, multiomics, AI in compound discovery and in experimental design, and bioconjugation approaches in oncology.
• Drug Discovery 2026 returns to ExCeL London from 14–15 October to celebrate 20 years of collaboration and inclusion
• Keynote programme includes presentation from Dr Sam Barrell CBE and panel discussion with Dr Anne Phelan, Dr Jason Mellad, Prof Sir Mene Pangalos and Prof Raghib Ali OBE
• Key topics include next-generation biophysics, microbes to medicines, multiomics, AI in compound discovery and experimental design, and bioconjugation approaches in oncology
Launched in 2017, the UK DRI stands as a beacon of scientific innovation, representing an unprecedented £300 million investment in dementia research—the largest of its kind in UK history. The purpose of the UK DRI is to transform the outlook for people living with or at risk of neurodegenerative conditions through research.
Applications are invited for a Research Associate in oligodendrocyte and neuroimmune epigenomics to join the lab of Dr Alexi Nott (https://nottgroup.com/index.html) in the UK DRI at Imperial.